Calcitonin Salmon

LongevityFDA-approved calcitonin receptor agonistEstablished

Calcitonin Salmon is an FDA-approved calcitonin receptor agonist. Calcitonin binds the calcitonin receptor on osteoclasts, producing rapid loss of the ruffled border and reduced bone resorption, and acts at the renal tubule to increase calcium excretion. The salmon sequence binds the human receptor with higher affinity and is cleared more slowly than human calcitonin, which is why the salmon form is the one used clinically.

Calculate Dose

For research use only.

Key Facts

CAS
—
Molecular Weight (MW)
3431.9 g/mol
Half-life
—
FDA status
Approved
Evidence level
FDA Approved
Human dose established
Yes
Administration Route
Subcutaneous · Intramuscular · Intranasal
Frequency
Once daily (Paget's disease, osteoporosis); every 6–12 hours (hypercalcemia)
Last updated
Nov 7, 2026
Reviewed
Nov 7, 2026

Research summary

Synthetic 32-amino-acid polypeptide identical to salmon calcitonin, approved for Paget disease of bone, hypercalcaemia, and postmenopausal osteoporosis in women more than five years past menopause.

Research evidence

  • Regulatory review (FDA label)4 reviewed sources
  • Controlled human trialsNone in reviewed sources
  • Early or uncontrolled human studiesNone in reviewed sources
  • Lab & animal studiesNone in reviewed sources
How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Calcitonin Salmon profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Calcitonin Salmon dosage evidence

Calcitonin salmon has FDA-approved human dosages. Miacalcin injection is 100 USP Units a day under the skin or into a muscle for Paget's disease of bone and for postmenopausal osteoporosis, and starts at 4 USP Units/kg every 12 hours for hypercalcemia (up to 8 USP Units/kg every 6 hours). The nasal spray for postmenopausal osteoporosis is one 200-unit spray a day, alternating nostrils.

FDA Approved
Dosage evidence summary for Calcitonin Salmon
Human dosing establishedYes
RouteSubcutaneous · Intramuscular · Intranasal
FrequencyOnce daily (Paget's disease, osteoporosis); every 6–12 hours (hypercalcemia)
Duration studiedContinuous for Paget's disease and osteoporosis, re-evaluated periodically
TitrationHypercalcemia: 4 USP Units/kg every 12 hours; 8 USP Units/kg every 12 hours after 1–2 days if needed; then up to 8 USP Units/kg every 6 hours.
Evidence levelFDA Approved
Last reviewed2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Calcitonin Salmon, one row per studied regimen
Study / contextPopulationDoseRouteFrequencyDurationOutcome studiedSource
FDA label — Miacalcin injection, Paget's disease of boneFDA-approved label · FDA prescribing informationAdults with symptomatic Paget's disease of bone when alternative treatments are not suitable100 USP Units (0.5 mL)Subcutaneous or intramuscularOnce dailyContinuous, re-evaluated periodicallyTreatment of Paget's diseaseMIACALCIN (calcitonin salmon) injection — FDA prescribing information, DailyMed
FDA label — Miacalcin injection, hypercalcemiaFDA-approved label · FDA prescribing informationPatients with hypercalcemiaStart 4 USP Units/kg; may increase to 8 USP Units/kg every 12 hours, then to a maximum of 8 USP Units/kg every 6 hoursSubcutaneous or intramuscularEvery 12 hours, up to every 6 hoursEarly treatment of hypercalcemiaLower serum calciumMIACALCIN (calcitonin salmon) injection — FDA prescribing information, DailyMed
FDA label — Miacalcin injection, postmenopausal osteoporosisFDA-approved label · FDA prescribing informationWomen more than 5 years past menopause with osteoporosis when alternative treatments are not suitable100 USP Units (0.5 mL)Subcutaneous or intramuscularOnce dailyContinuous, with calcium and vitamin DTreatment of postmenopausal osteoporosis; fracture reduction not demonstratedMIACALCIN (calcitonin salmon) injection — FDA prescribing information, DailyMed
FDA label — calcitonin salmon nasal spray (generic, Apotex), postmenopausal osteoporosisFDA-approved label · FDA prescribing information, genericWomen more than 5 years past menopause with osteoporosis when alternative treatments are not suitable1 spray (200 USP Units)Intranasal, alternating nostrils dailyOnce dailyContinuous, with calcium and vitamin DTreatment of postmenopausal osteoporosis; fracture reduction not demonstratedCalcitonin salmon nasal spray (Apotex) — FDA prescribing information, DailyMed

Where sources disagree

  • Doses are in USP Units, not micrograms, and injected and nasal doses differ (100 units injected versus 200 units sprayed). DailyMed lists no current brand-name nasal spray; the nasal row uses a generic label.
  • The labels report a higher rate of malignancy with calcitonin salmon than placebo in a meta-analysis of 21 trials (4.1% versus 2.9%), so they say to re-evaluate the need for continued therapy periodically.
Calcitonin Salmon dosage in published studies and labels →

Sequence & molecular data

Sequence and molecular data for Calcitonin Salmon
Molecular formulaC145H240N44O48S2
Molecular weight3431.9 g/mol
PubChem CID16220016
FDA UNII7SFC6U2VI5

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Calcitonin binds the calcitonin receptor on osteoclasts, producing rapid loss of the ruffled border and reduced bone resorption, and acts at the renal tubule to increase calcium excretion. The salmon sequence binds the human receptor with higher affinity and is cleared more slowly than human calcitonin, which is why the salmon form is the one used clinically.

Research statistics

1,766 PubMed publications · 31.3% human clinical research · 19 registered trials

Counts of published research through 2026-11-08, not evidence that it works. Publications by year, study types and trials · How publications are counted

Regulatory & research status

Calcitonin Salmon is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

Regulatory and research status for Calcitonin Salmon
FDA statusApproved
Research statusApproved product (see FDA status)
AvailabilityPrescription-Only
WADA (sport)Unknown / Not Listed
Library classificationFDA-Approved

How FDA approval, compounding and research-only status differ

Benefits

—

Calcitonin Salmon side effects

No side effects listed yet for this entry.

Storage & stability

This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.

Calcitonin Salmon: frequently asked questions

What is Calcitonin Salmon?

Synthetic 32-amino-acid polypeptide identical to salmon calcitonin, approved for Paget disease of bone, hypercalcaemia, and postmenopausal osteoporosis in women more than five years past menopause.

How does Calcitonin Salmon work?

Calcitonin binds the calcitonin receptor on osteoclasts, producing rapid loss of the ruffled border and reduced bone resorption, and acts at the renal tubule to increase calcium excretion. The salmon sequence binds the human receptor with higher affinity and is cleared more slowly than human calcitonin, which is why the salmon form is the one used clinically.

Is Calcitonin Salmon FDA approved?

Yes. Calcitonin Salmon is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

What peptides are similar to Calcitonin Salmon?

Compounds most often compared with Calcitonin Salmon include Elamipretide (SS-31) and Methylene Blue. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2

This Calcitonin Salmon profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Calcitonin Salmon research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →